Search Results for “ oncology” – Page 60 – media

NICE sticks with ‘no’ for earlier use of Halaven

Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.
- Source: pharmatimes
- 1,831
- February 23, 2018
breast cancer Market Views NHS
Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2017.
- Source: Merck
- 518
- February 19, 2018
Company Insight Merck
GSK delivers improvements in sales, margins and cash flow in 2017

GSK delivers improvements in sales, margins and cash flow in 2017：Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
- Source: GSK
- 494
- February 15, 2018
Company Insight GSK
Abbott supports Angle’s breast cancer liquid biopsy study

Healthcare firm Abbott will provide its PathVysion HER-2 DNA FISH probe kits for use in Angle's breast cancer liquid biopsy study.
- Source: invitrodiagnostics.medicaldevices-business-review
- 629
- February 13, 2018
Abbott breast cancer liquid biopsy Researches
Paige.AI Created to Transform Cancer Diagnosis and Treatment by Applying Artificial Intelligence to Pathology

Paige.AI, a new company focused on revolutionizing clinical diagnosis and treatment in oncology through use of artificial intelligence (AI), launches today as it announces two major milestones
- Source: tmcnet
- 563
- February 9, 2018
AI Market Views Series
Pfizer vs J&J– Researchers are duking it out for the championship title in nonmetastatic prostate cancer

Pfizer $PFE and J&J $JNJ have come down to the wire with pivotal data on nonmetastatic prostate cancer. And there are billions of dollars in revenue on the line here.
- Source: Endpts
- 457
- February 7, 2018
Market Views prostate cancer
Why AstraZeneca’s New Drug Strategy Seems to be Bearing Fruit

Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reutersreported Thursday.
- Source: china-pharmacy
- 489
- February 7, 2018
AstraZeneca New Drug Strategy
Nicotine in E-cigarettes damages DNA, mouse study suggests

The nicotine in e-cigarettes seems to damage DNA in ways that may increase cancer risk, a new study in mice suggests.
- Source: medicalxpress
- 610
- February 6, 2018
cancer DNA e-cigarettes nicotine Researches
Why healthcare cybersecurity spending will exceed $65B over the next 5 years

Hospitals and healthcare providers remain under cyber attack, causing organizations to spend more to protect their systems and patient data.
- Source: CSO Online
- 558
- February 6, 2018
cybersecurity digital health Market Views
NICE becomes latest champion for digital health

NICE has become the latest organisation to champion digital health, recommending that the NHS should trial an online and mobile programme to treat depression.
- Source: Pharma Phorum
- 745
- February 1, 2018
Company Insight digital health EHR NICE

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.